{"title":"MannKind终于在赛诺菲找到了吸入胰岛素Afrezza®的合作伙伴","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i9.2062","DOIUrl":null,"url":null,"abstract":"Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt. The drug will diversify Sanofi’s diabetes portfolio ahead of the 2015 patent expiry of its long-acting basal insulin analogue Lantus® (insulin glargine), which leads the diabetes market with sales of more than US$7 B in 2013. Considerable uncertainty surrounds the commercial potential of Afrezza, however.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2014i9.2062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt. The drug will diversify Sanofi’s diabetes portfolio ahead of the 2015 patent expiry of its long-acting basal insulin analogue Lantus® (insulin glargine), which leads the diabetes market with sales of more than US$7 B in 2013. Considerable uncertainty surrounds the commercial potential of Afrezza, however.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2014i9.2062\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2014i9.2062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi
Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt. The drug will diversify Sanofi’s diabetes portfolio ahead of the 2015 patent expiry of its long-acting basal insulin analogue Lantus® (insulin glargine), which leads the diabetes market with sales of more than US$7 B in 2013. Considerable uncertainty surrounds the commercial potential of Afrezza, however.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
